The Choice between Intravenous and Subcutaneous Immunoglobulins: Aspects for Consideration
Abstract Background: Intravenous immunoglobulin and subcutaneous immunoglobulin preparations are used to treat primary and secondary immunodeficiencies, as well as autoimmune and inflammatory conditions. Summary: For certain indications, only defined formulations or routes of administration are appr...
Gespeichert in:
| Veröffentlicht in: | Pharmacology 2022-12, Vol.107 (11-12), p.556-563 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 563 |
|---|---|
| container_issue | 11-12 |
| container_start_page | 556 |
| container_title | Pharmacology |
| container_volume | 107 |
| creator | von Achenbach, Caroline Hevia Hernandez, Giselle von Gunten, Stephan |
| description | Abstract
Background: Intravenous immunoglobulin and subcutaneous immunoglobulin preparations are used to treat primary and secondary immunodeficiencies, as well as autoimmune and inflammatory conditions. Summary: For certain indications, only defined formulations or routes of administration are approved by health authorities. However, for other diseases, there are more options, and treatment decisions may be based on different aspects, such as patient conditions and preferences, pharmacokinetics, or pharmacoeconomic considerations. Key Messages: Understanding the two different treatment modalities may support the decision-making for the optimal therapeutic option for individual patients. This review summarizes the latest insights into the direct and indirect comparison between the two types of products. |
| doi_str_mv | 10.1159/000527655 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_cross</sourceid><recordid>TN_cdi_gale_infotracacademiconefile_A729281477</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A729281477</galeid><sourcerecordid>A729281477</sourcerecordid><originalsourceid>FETCH-LOGICAL-c413t-1eaf5049953733ae71b1c8de61708f49570f36f79fd1060ee14dca4bac7a508d3</originalsourceid><addsrcrecordid>eNptkMFLwzAUxoMobk4P3j0EdvLQmTRt03obRd1goOC8eClp-rJF22QkreJ_b0dlIIx3-OD7ft_j8RC6pmRGaZzdEULikCdxfILGNApZQBhlp2hMeg04oeEIXXj_0WNJyNNzNGIJizKekTF6X28B51urJeAS2m8Ag5emdeILjO08FqbCr10pu1YY2BvLpumM3dS27Gpt_D2e-x3I1mNlHc6t8boCJ1ptzSU6U6L2cPWnE_T2-LDOF8Hq-WmZz1eBjChrAwpCxSTKsphxxgRwWlKZVpBQTlIVZTEniiWKZ6qiJCEANKqkiEohuYhJWrEJmg57N6KGQhtl-_Nlo70s5jzMwpRGnPfU7AjVTwWNltaA0r3_r3A7FKSz3jtQxc7pRrifgpJi__bi8PaevRnYT-E24A7kIZ4ejV8W84EodpViv9G6h0Q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>The Choice between Intravenous and Subcutaneous Immunoglobulins: Aspects for Consideration</title><source>Karger Journals</source><creator>von Achenbach, Caroline ; Hevia Hernandez, Giselle ; von Gunten, Stephan</creator><creatorcontrib>von Achenbach, Caroline ; Hevia Hernandez, Giselle ; von Gunten, Stephan</creatorcontrib><description>Abstract
Background: Intravenous immunoglobulin and subcutaneous immunoglobulin preparations are used to treat primary and secondary immunodeficiencies, as well as autoimmune and inflammatory conditions. Summary: For certain indications, only defined formulations or routes of administration are approved by health authorities. However, for other diseases, there are more options, and treatment decisions may be based on different aspects, such as patient conditions and preferences, pharmacokinetics, or pharmacoeconomic considerations. Key Messages: Understanding the two different treatment modalities may support the decision-making for the optimal therapeutic option for individual patients. This review summarizes the latest insights into the direct and indirect comparison between the two types of products.</description><identifier>ISSN: 0031-7012</identifier><identifier>EISSN: 1423-0313</identifier><identifier>DOI: 10.1159/000527655</identifier><identifier>PMID: 36349790</identifier><language>eng</language><publisher>Basel, Switzerland: S. Karger AG</publisher><subject>Analysis ; Autoimmunity ; Care and treatment ; Decision-making ; Health aspects ; Homeopathy ; Immunodeficiency ; Immunoglobulins ; Materia medica and therapeutics ; Patient compliance ; Respiratory agents ; Review Article ; Therapeutics</subject><ispartof>Pharmacology, 2022-12, Vol.107 (11-12), p.556-563</ispartof><rights>2022 S. Karger AG, Basel</rights><rights>COPYRIGHT 2022 S. Karger AG</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c413t-1eaf5049953733ae71b1c8de61708f49570f36f79fd1060ee14dca4bac7a508d3</citedby><orcidid>0000-0001-8801-9440 ; 0000-0002-2753-8738</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,2429,27924,27925</link.rule.ids></links><search><creatorcontrib>von Achenbach, Caroline</creatorcontrib><creatorcontrib>Hevia Hernandez, Giselle</creatorcontrib><creatorcontrib>von Gunten, Stephan</creatorcontrib><title>The Choice between Intravenous and Subcutaneous Immunoglobulins: Aspects for Consideration</title><title>Pharmacology</title><addtitle>Pharmacology</addtitle><description>Abstract
Background: Intravenous immunoglobulin and subcutaneous immunoglobulin preparations are used to treat primary and secondary immunodeficiencies, as well as autoimmune and inflammatory conditions. Summary: For certain indications, only defined formulations or routes of administration are approved by health authorities. However, for other diseases, there are more options, and treatment decisions may be based on different aspects, such as patient conditions and preferences, pharmacokinetics, or pharmacoeconomic considerations. Key Messages: Understanding the two different treatment modalities may support the decision-making for the optimal therapeutic option for individual patients. This review summarizes the latest insights into the direct and indirect comparison between the two types of products.</description><subject>Analysis</subject><subject>Autoimmunity</subject><subject>Care and treatment</subject><subject>Decision-making</subject><subject>Health aspects</subject><subject>Homeopathy</subject><subject>Immunodeficiency</subject><subject>Immunoglobulins</subject><subject>Materia medica and therapeutics</subject><subject>Patient compliance</subject><subject>Respiratory agents</subject><subject>Review Article</subject><subject>Therapeutics</subject><issn>0031-7012</issn><issn>1423-0313</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNptkMFLwzAUxoMobk4P3j0EdvLQmTRt03obRd1goOC8eClp-rJF22QkreJ_b0dlIIx3-OD7ft_j8RC6pmRGaZzdEULikCdxfILGNApZQBhlp2hMeg04oeEIXXj_0WNJyNNzNGIJizKekTF6X28B51urJeAS2m8Ag5emdeILjO08FqbCr10pu1YY2BvLpumM3dS27Gpt_D2e-x3I1mNlHc6t8boCJ1ptzSU6U6L2cPWnE_T2-LDOF8Hq-WmZz1eBjChrAwpCxSTKsphxxgRwWlKZVpBQTlIVZTEniiWKZ6qiJCEANKqkiEohuYhJWrEJmg57N6KGQhtl-_Nlo70s5jzMwpRGnPfU7AjVTwWNltaA0r3_r3A7FKSz3jtQxc7pRrifgpJi__bi8PaevRnYT-E24A7kIZ4ejV8W84EodpViv9G6h0Q</recordid><startdate>20221201</startdate><enddate>20221201</enddate><creator>von Achenbach, Caroline</creator><creator>Hevia Hernandez, Giselle</creator><creator>von Gunten, Stephan</creator><general>S. Karger AG</general><scope>AAYXX</scope><scope>CITATION</scope><orcidid>https://orcid.org/0000-0001-8801-9440</orcidid><orcidid>https://orcid.org/0000-0002-2753-8738</orcidid></search><sort><creationdate>20221201</creationdate><title>The Choice between Intravenous and Subcutaneous Immunoglobulins: Aspects for Consideration</title><author>von Achenbach, Caroline ; Hevia Hernandez, Giselle ; von Gunten, Stephan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c413t-1eaf5049953733ae71b1c8de61708f49570f36f79fd1060ee14dca4bac7a508d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Analysis</topic><topic>Autoimmunity</topic><topic>Care and treatment</topic><topic>Decision-making</topic><topic>Health aspects</topic><topic>Homeopathy</topic><topic>Immunodeficiency</topic><topic>Immunoglobulins</topic><topic>Materia medica and therapeutics</topic><topic>Patient compliance</topic><topic>Respiratory agents</topic><topic>Review Article</topic><topic>Therapeutics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>von Achenbach, Caroline</creatorcontrib><creatorcontrib>Hevia Hernandez, Giselle</creatorcontrib><creatorcontrib>von Gunten, Stephan</creatorcontrib><collection>CrossRef</collection><jtitle>Pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>von Achenbach, Caroline</au><au>Hevia Hernandez, Giselle</au><au>von Gunten, Stephan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Choice between Intravenous and Subcutaneous Immunoglobulins: Aspects for Consideration</atitle><jtitle>Pharmacology</jtitle><addtitle>Pharmacology</addtitle><date>2022-12-01</date><risdate>2022</risdate><volume>107</volume><issue>11-12</issue><spage>556</spage><epage>563</epage><pages>556-563</pages><issn>0031-7012</issn><eissn>1423-0313</eissn><abstract>Abstract
Background: Intravenous immunoglobulin and subcutaneous immunoglobulin preparations are used to treat primary and secondary immunodeficiencies, as well as autoimmune and inflammatory conditions. Summary: For certain indications, only defined formulations or routes of administration are approved by health authorities. However, for other diseases, there are more options, and treatment decisions may be based on different aspects, such as patient conditions and preferences, pharmacokinetics, or pharmacoeconomic considerations. Key Messages: Understanding the two different treatment modalities may support the decision-making for the optimal therapeutic option for individual patients. This review summarizes the latest insights into the direct and indirect comparison between the two types of products.</abstract><cop>Basel, Switzerland</cop><pub>S. Karger AG</pub><pmid>36349790</pmid><doi>10.1159/000527655</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0001-8801-9440</orcidid><orcidid>https://orcid.org/0000-0002-2753-8738</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0031-7012 |
| ispartof | Pharmacology, 2022-12, Vol.107 (11-12), p.556-563 |
| issn | 0031-7012 1423-0313 |
| language | eng |
| recordid | cdi_gale_infotracacademiconefile_A729281477 |
| source | Karger Journals |
| subjects | Analysis Autoimmunity Care and treatment Decision-making Health aspects Homeopathy Immunodeficiency Immunoglobulins Materia medica and therapeutics Patient compliance Respiratory agents Review Article Therapeutics |
| title | The Choice between Intravenous and Subcutaneous Immunoglobulins: Aspects for Consideration |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T08%3A50%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Choice%20between%20Intravenous%20and%20Subcutaneous%20Immunoglobulins:%20Aspects%20for%20Consideration&rft.jtitle=Pharmacology&rft.au=von%20Achenbach,%20Caroline&rft.date=2022-12-01&rft.volume=107&rft.issue=11-12&rft.spage=556&rft.epage=563&rft.pages=556-563&rft.issn=0031-7012&rft.eissn=1423-0313&rft_id=info:doi/10.1159/000527655&rft_dat=%3Cgale_cross%3EA729281477%3C/gale_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/36349790&rft_galeid=A729281477&rfr_iscdi=true |